Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389876 | 0.85 | HTR2A (0.55) | HTR2ARETSLC6A3HTR2CEGFR | |
| Hydrochloric Acid SCHEMBL10743675 | 0.83 | HTR2A (0.53) | HTR2ARETSLC6A3HTR2CEGFR | |
| SCHEMBL10962986 | 0.83 | HTR2A (0.41) | HTR2ARETSLC6A3HTR2CLMNA | |
| SCHEMBL9245535 | 0.82 | HTR2A (0.46) | HTR2ARETSLC6A3HTR2CEGFR | |
| Hydrochloric Acid SCHEMBL9247364 | 0.81 | RET (0.45) | HTR2ARETSLC6A3HTR2CEGFR | |
| SCHEMBL11229958 | 0.76 | MEN1 (0.44) | HTR2ARETMEN1KMT2AACP3 | |
| SCHEMBL14407922 | 0.75 | HTR2A (0.55) | HTR2AHTR2CEGFRHRH1 | |
| SCHEMBL9247924 | 0.71 | ANPEP (0.44) | HTR2ARETHTR2CEGFRHRH1 | |
| SCHEMBL10743668 | 0.71 | HTR2A (0.53) | HTR2ARETSLC6A3HTR2CSMN1; SMN2 | |
| SCHEMBL11993914 | 0.70 | HTR2A (0.53) | HTR2ARETSLC6A3HTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455698-B1 | FOR TREATING CEREBRAL ISCHEMIA OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, NEURODEGENERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | KORNBERG BRIAN EDWARD (US) | 2002-05-30 | — | — | US | disclosed |
| US-6340758-B1 | DRUGS AS NEUROPROTECTIVE AGENTS INVENTION MAY ALSO BE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, EPILEPSY, ANXIETY, PAIN AND DRUG ADDICTION. | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-5449778-A | Peptide intermediates | WARNER-LAMBERT COMPANY (US) | 1995-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | CBR1, CBR3, CHRNA7 | HTR2A 399/4885RET 4093/4885GID4 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.